DPM1-CDG is a rare inherited condition that usually starts in infancy and affects how the body adds sugar chains to proteins. Early signs of DPM1-CDG can include low muscle tone, feeding problems, developmental delay, and seizures, and some children also have vision or movement problems. Not everyone will have the same experience. DPM1-CDG is lifelong, and the outlook can vary widely, with severe cases carrying a risk of life-threatening complications while milder cases may be more stable. Treatment for DPM1-CDG focuses on managing symptoms with supportive care such as seizure treatment, nutrition support, physical therapy, and monitoring by specialists.
How many people live with Dpm1-cdg?
There is no reliable recent estimate of how many people are living with DPM1-CDG worldwide (Orphanet, 2024), and no separate recent U.S. estimate is consistently reported either (GARD, 2024). It is considered extremely rare, with only a very small number of people and families described in the medical literature.
Overview
Dpm1-cdgSymptoms
DPM1-CDG often causes weak muscle tone, delayed development, and seizures from infancy. Many living with DPM1-CDG also have feeding problems, poor growth, vision changes, or movement difficulties, though features can vary from child to child.
Outlook and prognosis
DPM1-CDG often means lifelong developmental and movement challenges, and many people need ongoing therapy and daily support. Outlook varies widely: some children survive into adulthood, while severe early seizures, feeding problems, or organ involvement can shorten life.
Causes and risk factors
DPM1-CDG is caused by changes in both copies of the DPM1 gene, usually inherited from each parent. It often starts before birth. Lifestyle and environmental factors do not cause DPM1-CDG, but infections and poor nutrition can worsen complications.
Genetic influences
Genetics are central to Dpm1-cdg because it is caused by changes in the DPM1 gene. Many people with Dpm1-cdg inherit one changed copy from each parent, so family testing and genetic counseling can help clarify risks.
Diagnosis
DPM1-CDG is usually suspected from clinical features, developmental concerns, and abnormal lab results. Doctors often confirm the diagnosis of DPM1-CDG with genetic tests. Brain imaging or other tests may help show how the condition affects the body.
Treatment and drugs
DPM1-CDG treatment focuses on daily support and careful follow-up. Many living with DPM1-CDG need seizure medicines, feeding and nutrition support, and physical, occupational, or speech therapy. Care is tailored to symptoms and monitored by several specialists.
Symptoms
DPM1-CDG often shows up early in life through differences in movement, learning, feeding, and sometimes vision. Many people with DPM1-CDG have low muscle tone and developmental delay, and some also have seizures or a smaller-than-expected head size. The early features of DPM1-CDG can look different from child to child. Features vary from person to person and can change over time.
Learning, speech, and motor skills often develop more slowly than expected. Some children need extra support for communication, school, and everyday tasks.
Babies may feel floppy when held and may take longer to roll, sit, or walk. As children grow, low muscle tone can make posture, balance, and physical activity more tiring.
Some people with DPM1-CDG have seizures, which can begin in infancy or childhood. These episodes can look very different from one child to another, so medical evaluation is important.
Head growth may be slower than expected, leading to a smaller head size for age. In medical terms, this is microcephaly, and it often appears alongside developmental differences.
How people usually first notice Dpm1-cdg?
The first signs of DPM1-CDG are usually noticed in infancy, often when a baby has poor feeding, weak muscle tone, slow growth, or is not meeting early developmental milestones such as head control or rolling. Many living with DPM1-CDG are first brought to medical attention because of seizures, unusual floppiness, or delays that seem more pronounced than expected in the first months of life. How DPM1-CDG is first noticed can vary, but doctors and families often recognize a pattern of early neurologic and developmental concerns rather than one single sign.
Types of Dpm1-cdg
No distinct types of DPM1-CDG are widely recognized.
Can I slow down the onset of symptoms?
No, there is no good evidence that lifestyle changes or current medical treatment can meaningfully delay the start of symptoms in DPM1-CDG. This is a rare inherited condition that is present from birth, so things like diet, exercise, sleep, or vitamins may support overall health but are not known to prevent or postpone when symptoms begin; research into better treatments is still ongoing. There are no proven medicines or routine screening steps that can stop symptoms from starting, but early follow-up with experienced specialists can help find problems sooner and manage them as well as possible.
What genetics can tell you about symptoms
In DPM1-CDG, genetics can give some clues about symptoms, but they do not predict everything with certainty. Different changes in the DPM1 gene can affect how much the gene still works, and this may influence which problems show up, how severe they are, and whether symptoms begin in infancy or later in childhood; in general, less remaining gene function is linked with more serious neurologic and developmental problems. Even so, this condition is very rare, so many living with DPM1-CDG can have a different mix of symptoms even when the gene changes seem similar.
Causes and risk factors
The cause of DPM1-CDG is a change in the DPM1 gene, which disrupts how cells attach certain sugars to proteins. DPM1-CDG is usually inherited in an autosomal recessive pattern, so a child is affected only after getting one changed copy from each parent, who are often healthy carriers. Because of this, family history is the main risk factor, especially when a couple wants to understand the risk of DPM1-CDG in future pregnancies. Lifestyle and environmental factors are not known to cause DPM1-CDG, though other genes and body factors may affect how severe it is. Genetic testing can sometimes clarify your personal risk.
What are the most common causes or risk factors?
DPM1-CDG is caused by inheriting two nonworking copies of the DPM1 gene, one from each parent. The main risk factors are having parents who each carry one silent copy of this gene change, having a family history of the condition, or having parents who are related by blood, which can make the same rare gene change more likely in both parents. There are no known lifestyle, diet, or pregnancy-related causes.
Environmental and biological risk factors
For DPM1-CDG, the list of proven environmental and non-genetic biological risk factors is very short. Doctors often group risks into internal (biological) and external (environmental). With DPM1-CDG, researchers have not identified common outside exposures, pregnancy conditions, or birth events that clearly raise the chance of the condition.
No medicine, infection, pollution, or chemical exposure has been proven to cause DPM1-CDG. This means there are no well-established environmental risk factors that families can clearly avoid.
Unlike some chromosome conditions, older maternal or paternal age is not known to increase the chance of DPM1-CDG. Current evidence does not show a clear age-related pattern.
Common maternal health problems during pregnancy, such as diabetes, high blood pressure, or routine infections, have not been shown to specifically raise the risk of DPM1-CDG. Researchers have not identified a consistent pregnancy-related trigger.
Prematurity, delivery complications, and low oxygen around birth are not known to be causes of DPM1-CDG. These events can affect a baby's health, but they are not established risk factors for this condition.
Genetic risk factors
For families facing DPM1-CDG, the main risks come from inherited changes in one gene called DPM1. This condition usually happens when a child receives two nonworking copies of DPM1, one from each parent. Carrying a genetic change doesn’t guarantee the condition will appear, because people with just one changed copy are usually healthy carriers. Knowing the genetic causes of DPM1-CDG can help families understand recurrence risk and when genetic counseling may be useful.
DPM1 gene: DPM1-CDG is caused by harmful changes in the DPM1 gene. This gene helps cells build and attach certain sugar chains to proteins, so changes in both copies can disrupt many body systems.
Recessive inheritance: DPM1-CDG follows an autosomal recessive pattern. This means a child is affected only when they inherit one changed DPM1 copy from each parent.
Carrier parents: Parents who each carry one changed DPM1 copy usually do not have symptoms. With each pregnancy, there is a 25% chance the child will have DPM1-CDG, a 50% chance the child will be a healthy carrier, and a 25% chance the child will inherit neither changed copy.
Family history: A family history of DPM1-CDG or known DPM1 changes raises the chance that relatives may also be carriers. This is often the clearest clue when asking who is at risk for DPM1-CDG.
Affected sibling: If one child in a family has DPM1-CDG, full brothers and sisters have a higher chance of being affected than the general population. Even when siblings are not affected, they may still be carriers.
Related parents: When parents are biologically related, the chance that both carry the same rare DPM1 change is higher. This can increase the risk of autosomal recessive conditions such as DPM1-CDG.
Lifestyle risk factors
DPM1-CDG is a genetic condition, so lifestyle habits do not cause it. However, daily routines can still influence comfort, safety, nutrition, mobility, and the chance of complications. For families asking how lifestyle affects DPM1-CDG, the most helpful focus is on supportive habits that match the person’s neurologic, feeding, and physical needs.
Feeding difficulties can worsen poor growth, low energy, and recovery after illness in people with DPM1-CDG. Regular meals, texture changes, or tube-feeding plans may help maintain nutrition and reduce stress on the body.
Poor fluid intake can make weakness, constipation, and overall fatigue harder to manage. Good hydration may also support safer swallowing plans and help during hot weather or minor illnesses.
Gentle physical activity and physiotherapy-based movement can help preserve flexibility, joint range, and day-to-day function. Overexertion or unsafe activity may increase falls, fatigue, or injury when balance and muscle control are affected.
Irregular or poor-quality sleep can make daytime fatigue, irritability, and neurologic symptoms harder to cope with. A consistent sleep schedule may improve energy, participation in therapy, and overall symptom management.
Risk prevention
DPM1-CDG is a rare inherited condition, so there is usually no way to prevent the condition itself from occurring in someone who is born with it. For many living with DPM1-CDG, prevention means lowering the risk of complications such as infections, poor growth, seizures, injuries from low muscle tone, and nutrition problems. Prevention is flexible—it adapts to your life and health background. Early, regular care can also make the early symptoms of DPM1-CDG easier to spot and treat before they cause bigger setbacks.
Scheduled visits with a metabolic or neurology team can catch changes early and help prevent complications of DPM1-CDG. This often includes tracking growth, development, feeding, movement, and seizure control over time.
People with DPM1-CDG may do better when routine vaccines, handwashing, and quick treatment of fevers or breathing symptoms are part of daily care. Prevention works best when combined with regular check-ups.
Feeding support can help prevent choking, dehydration, and poor weight gain in DPM1-CDG. Some may need a swallowing review, texture changes, or extra nutrition if meals are tiring or slow.
Taking seizure medicines exactly as prescribed can lower the risk of breakthrough seizures and emergency visits in people with DPM1-CDG. Families can also help by avoiding missed doses and having a clear plan for what to do if a seizure happens.
Can you prevent Dpm1-cdg?
No, DPM1-CDG cannot usually be prevented because it is a rare inherited condition caused by a change in a gene that is present from the start of life. There are no proven lifestyle changes that can stop it from happening. If DPM1-CDG runs in your family, genetic counseling and testing before or during pregnancy may help you understand the chance of it happening again.
Transmission
DPM1-CDG is a genetic condition, not an infection, so it does not spread from person to person through touch, coughing, sex, food, or shared spaces. The key question is how DPM1-CDG is inherited: it usually happens when a child is born with two altered copies of the DPM1 gene, one passed down from each parent.
Most parents are healthy carriers, meaning they have one altered copy and one working copy. When both parents are carriers, each pregnancy has a 25% chance of DPM1-CDG, a 50% chance that the child will be an unaffected carrier, and a 25% chance that the child will inherit two working copies.
When to test your genes
Consider genetic testing for DPM1-CDG early if a baby or child has unexplained low muscle tone, developmental delay, seizures, feeding or growth problems, or a family history of the condition. A confirmed result can end the diagnostic search, guide supportive care, and help with recurrence-risk counseling for future pregnancies.
Diagnosis
Many living with DPM1-CDG come to medical attention because a baby is not meeting milestones, has low muscle tone, or has feeding and growth problems that do not fit a more common cause. Doctors usually begin with a careful review of symptoms, pregnancy and birth history, and a physical exam, because the diagnosis of DPM1-CDG often starts with a pattern of features rather than one single sign. Since this is a rare inherited condition, testing is usually needed to confirm what is causing the symptoms.
Doctors look at the overall pattern of signs, such as developmental delay, weak muscle tone, seizures, feeding trouble, and growth concerns. Certain facial features or problems affecting more than one body system can raise suspicion for DPM1-CDG.
A detailed exam checks muscle tone, reflexes, movement, balance, and how a child is developing over time. This helps show which parts of the nervous system may be affected and whether the findings fit a congenital disorder of glycosylation.
Specialized blood tests can look for abnormal glycosylation, which means the body is not attaching sugar chains to proteins in the usual way. These tests are often an important early step in the genetic diagnosis of DPM1-CDG.
Genetic tests are used to look for changes in the DPM1 gene that cause DPM1-CDG. Finding disease-causing variants confirms the diagnosis and can help with family counseling.
How is Dpm1-cdg diagnosed?
DPM1-CDG is usually suspected in a baby or child with signs like developmental delay, low muscle tone, seizures, feeding trouble, or other problems that affect more than one part of the body. Doctors often start with a blood test that checks whether certain proteins have the normal sugar attachments, because this condition affects the way the body makes and uses these sugar-linked proteins. The diagnosis is then confirmed with genetic testing of the DPM1 gene, and other tests may be done to look at the brain, eyes, or nerves and to rule out similar conditions.
Stages of Dpm1-cdg
Dpm1-cdg does not have defined progression stages. This is because it is a genetic condition that can affect development and body systems in different ways from early life, rather than moving through a standard step-by-step pattern over time. Doctors usually start with a conversation about symptoms and development, then use blood tests, physical exams, and often genetic testing to confirm the diagnosis. Because signs can vary from one person to another, follow-up usually focuses on tracking day-to-day function, growth, movement, seizures if present, and other health issues rather than looking for early symptoms of Dpm1-cdg in fixed stages.
Outlook and prognosis
The outlook for people with DPM1-CDG is highly variable and depends on how severely the nervous system, muscles, and other organs are affected. Individuals with early-onset, multisystem disease often have significant developmental impairment, seizures, low muscle tone, feeding difficulties, and progressive disability, which can lead to substantial medical complexity. In the more severe forms, recurrent infections, respiratory problems, and complications of profound neurologic involvement can shorten life expectancy, and deaths in infancy or childhood have been reported. Milder presentations may allow survival into later childhood or adulthood, but affected people usually continue to need long-term supportive care and rehabilitation. Because DPM1-CDG is very rare, precise survival statistics are not available, and prognosis is best estimated from the individual pattern of symptoms and response to supportive treatment.
Long-term effects
For many living with DPM1-CDG, day-to-day life is shaped most by long-term effects on development, movement, feeding, and the nervous system. Long-term effects vary widely, but this condition is often severe and usually starts early in life. Children who survive infancy often continue to have significant health and developmental needs as they grow. Because DPM1-CDG is very rare, the long-term effects of DPM1-CDG are still being described, especially into adulthood.
Many people with DPM1-CDG have lasting delays in learning, speech, and everyday skills. Some remain highly dependent on caregivers for communication, mobility, and daily care.
Seizures can be an ongoing feature and may continue over time. In some children, they are hard to control and can add to developmental and neurologic difficulties.
Low muscle tone often affects posture, head control, and coordinated movement from early life onward. As children get older, this can mean delayed sitting, standing, or walking, and some may never walk independently.
Feeding problems may persist and can make meals slow, tiring, or unsafe because of trouble sucking, swallowing, or coordinating eating. Over time, this can contribute to poor growth and low weight gain.
How is it to live with Dpm1-cdg?
Living with DPM1-CDG often means managing a condition that affects many parts of the body at once, so daily life can include therapies, frequent medical visits, help with feeding, and support for movement, communication, or learning. Many people living with DPM1-CDG have low muscle tone, developmental delay, and sometimes seizures or vision problems, which can make routines slower and more unpredictable but also highly structured around what helps them feel safest and strongest. For families and other close caregivers, this can mean extra coordination, hands-on care, and emotional strain, yet it also often builds deep expertise, close teamwork, and a strong focus on small but meaningful gains.
Treatment and drugs
DPM1-CDG is usually treated with supportive care, which means managing the symptoms and helping with daily function rather than fixing the underlying genetic change. Treatment often looks different for each person, but it may include medicines for seizures, feeding support if eating is hard, physical and occupational therapy for movement and muscle tone, and regular follow-up with specialists such as neurology, nutrition, and eye doctors. For many people, treatment begins with small daily steps, like adjusting meals, using therapy to build skills, and watching closely for problems such as poor growth or infections. Because DPM1-CDG can affect several parts of the body, care often works best when a team of doctors and therapists follows changes over time and updates the plan as needed.
Can you cure Dpm1-cdg?
There is no cure right now for DPM1-CDG. Treatment cannot remove the condition, but it can help manage problems such as seizures, feeding troubles, weak or floppy muscles, movement issues, and delays in learning and development. For many living with DPM1-CDG, care is focused on improving comfort, day-to-day function, and quality of life with support from a team of specialists.
Non-drug treatment
Daily care for DPM1-CDG usually centers on helping with movement, feeding, communication, learning, and safety at home and school. Supportive therapies can improve comfort, make everyday tasks easier, and help children reach their own best level of function. Because DPM1-CDG can affect people in different ways, care is usually tailored to the symptoms a child has and how severe they are. Many living with DPM1-CDG do best with a coordinated team that reviews needs regularly as they grow.
Physical therapy can help with low muscle tone, stiffness, balance problems, and delayed motor skills. For many, this can mean working on sitting, standing, walking, and safer transfers during daily routines.
Occupational therapy focuses on hand use, dressing, bathing, play, and other everyday activities. It can also help with positioning and suggest tools or home changes that make daily life easier.
Speech and language therapy can support communication, whether a child uses speech, gestures, pictures, or a device. If early symptoms of DPM1-CDG include feeding trouble, speech therapists may also help assess oral skills needed for safer eating and drinking.
Feeding therapy and dietitian care can help if meals are slow, tiring, or linked to poor weight gain. Some children need texture changes, high-calorie plans, or tube feeding support to get enough nutrition safely.
Your genes may have an impact on how drugs work for you
For people living with DPM1-CDG, there is no well-established evidence that this condition has a specific, predictable effect on how common medicines work based on their genes. In day-to-day care, medicine choices are usually guided more by the health problems that come with the condition, such as seizures, liver problems, muscle weakness, or feeding difficulties, because these can change how safely a drug can be used and how strongly side effects are felt. For example, if someone with DPM1-CDG is already very sleepy, weak, or has liver trouble, doctors may start with lower doses and watch more closely.
Pharmacological treatments
Treatment for DPM1-CDG is usually aimed at easing symptoms, because there is currently no medicine that fixes the underlying problem in this condition. The drugs used depend on what is affecting daily life most, such as seizures, feeding-related reflux, constipation, sleep trouble, or muscle stiffness. Not everyone responds to the same medication in the same way, so treatment for DPM1-CDG is often individualized and adjusted over time.
If seizures are part of DPM1-CDG, doctors often use anti-seizure drugs such as levetiracetam, valproic acid, or clobazam. The best choice depends on the seizure type, age, and side effect profile.
Many living with DPM1-CDG who spit up often, arch after feeds, or seem uncomfortable with meals may be given omeprazole, lansoprazole, or famotidine. These medicines can lower stomach acid and help protect the esophagus.
Constipation is often treated with medicines such as polyethylene glycol or lactulose when bowel movements are hard, painful, or infrequent. For many, this can mean less belly pain, easier feeding, and less day-to-day distress.
If tight muscles or spasms make positioning, dressing, or therapy harder, baclofen or diazepam may be used. These medicines can reduce stiffness, but they may also cause sleepiness or low muscle tone in some people.
Genetic influences
In DPM1-CDG, the genetic cause is known: changes in the DPM1 gene disrupt an important step the body uses to add sugar chains to proteins, which cells need in order to work normally. This condition is usually inherited in an autosomal recessive pattern, which means a child develops DPM1-CDG after inheriting one changed copy of the gene from each parent. A carrier means you hold the gene change but may not show symptoms, so parents often have no warning that they carry it.
When both parents are carriers, each pregnancy has a 1 in 4, or 25%, chance of DPM1-CDG, a 1 in 2, or 50%, chance of a child who is also a carrier, and a 1 in 4, or 25%, chance of a child without the family gene change. Many living with DPM1-CDG can be affected in different ways, even within the same family, partly because different gene changes can disrupt the gene to different degrees. Genetic testing can confirm the diagnosis and help relatives understand carrier status, recurrence risk, and whether genetic counseling may be useful.
Is Dpm1-cdg genetic?
Genetics are central to Dpm1-cdg because it is caused by changes in the DPM1 gene. Many people with Dpm1-cdg inherit one changed copy from each parent, so family testing and genetic counseling can help clarify risks.
Having a genetic risk is not necessarily a diagnosis
Across the general population, genetic variants are common and are a normal part of human biology. Most do not directly affect health and instead are part of natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a definitive diagnosis, especially when several genes and environmental factors play a role. Still, in some cases, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with DPM1-CDG, treatment is usually shaped by the symptoms affecting daily life most, such as seizures, low muscle tone, feeding trouble, or developmental needs, rather than by one standard drug for the condition itself. The genetic result matters because confirming a change in the DPM1 gene helps doctors know they are dealing with DPM1-CDG and can plan care around the body systems most likely to need support. At this time, there is no widely established medicine that corrects the underlying gene change in DPM1-CDG, so treatment is mainly supportive and may include anti-seizure medicines, nutrition support, and physical, occupational, or speech therapy. Genetics is only one factor, because age, overall health, liver function, and other medicines can also change how well a treatment works or how likely side effects are. Since DPM1-CDG is very rare, there are no routine, well-proven pharmacogenetic tests that reliably tell doctors which everyday medicines will work best for each person with this condition. Still, knowing the exact gene change can help families understand the diagnosis, guide genetic counseling, and sometimes show whether someone may qualify for research studies or emerging treatments.
Interactions with other conditions
For many living with DPM1-CDG, everyday health problems can become more complicated when another illness is present. Chest infections may be harder to recover from because some people with DPM1-CDG have low muscle tone, weakness, or swallowing problems, which can make it harder to clear the airway and can raise the risk of food or liquid going into the lungs. Seizure disorders can also interact with DPM1-CDG, since fever, dehydration, or infection may trigger seizures more easily and leave someone feeling wiped out for longer afterward. Doctors call it a comorbidity when two conditions occur together. Feeding difficulties and reflux, which can be among the early symptoms of DPM1-CDG, may add to poor growth and can increase the chance of aspiration pneumonia. Because DPM1-CDG can affect several body systems, care often works best when neurology, nutrition, and other specialists coordinate treatment if heart, liver, or breathing problems are also present.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Dpm1-cdg?
Because DPM1-CDG can cause delayed development, low muscle tone, seizures, and feeding problems, it can look like other rare inherited conditions, especially other CDG disorders such as PMM2-CDG, as well as mitochondrial disorders, which affect how cells make energy. In some children, doctors may also need to rule out cerebral palsy and certain muscle disorders that can also cause floppy muscles and delayed milestones.
History
Long before DPM1-CDG had its current name, doctors were describing infants and children with a puzzling mix of problems that did not seem to fit better-known conditions. Some had very low muscle tone, delays in movement and learning, seizures, or trouble with growth and feeding. In recent decades, awareness has grown as doctors learned that these patterns can be part of a larger group of conditions called congenital disorders of glycosylation, or CDG.
That broader CDG group began to take shape in the late 20th century, when improved lab testing showed that some children were having trouble with the body’s normal process of attaching sugar chains to proteins. This process is important in many organs, which helped explain why the signs could affect the brain, muscles, hormones, and other body systems at the same time. As testing improved, researchers were able to sort this broad category into smaller, more specific types, including DPM1-CDG.
How DPM1-CDG was first recognized reflects that shift in medicine from describing symptoms alone to linking them with an underlying biological problem. Early reports were based on the day-to-day challenges families and clinicians could see, such as a baby who felt unusually floppy, missed expected milestones, or had seizures that were hard to explain. Later, specialized laboratory studies and genetic research showed that these children shared the same rare disorder, which allowed the condition to be identified more clearly.
Because DPM1-CDG is very rare, its history is still developing. Each newly described case has helped doctors understand the range of symptoms better, including the early symptoms of DPM1-CDG and how they can differ from one child to another. For many living with DPM1-CDG, this growing knowledge has mattered in practical ways: it can shorten the path to diagnosis, guide supportive care, and help families get clearer information than was available in the past.